DAPT Score for Dual Antiplatelet Therapy Duration
Balances ischaemic benefit vs bleeding risk of prolonged dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement. Guides decision to continue or stop DAPT after 12 months.
Score interpretation
→ DAPT Score ≥2: Ischaemic benefit outweighs bleeding risk. Continue DAPT for up to 30 months after DES. Assess bleeding risk (HAS-BLED) in parallel. Use aspirin 75–100 mg + P2Y12 inhibitor (clopidogrel or ticagrelor).
→ DAPT Score <2: Bleeding risk outweighs ischaemic benefit. Discontinue P2Y12 inhibitor at 12 months. Continue aspirin monotherapy indefinitely. Consider gastric protection (PPI) if high GI bleeding risk.
Interpretation bands for the DAPT Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Ticagrelor · Antiplatelet
- Clopidogrel (ACS / Post-PCI) · Antiplatelet / ACS
- Clopidogrel (Loading Dose) · P2Y12 Inhibitor Antiplatelet — ACS
- Clopidogrel (Elderly) · Antiplatelet — P2Y12 Inhibitor
- Clopidogrel (Stroke/TIA Secondary Prevention) · Antiplatelet (P2Y12 Inhibitor)
- Vorasidenib (Specialist drug) · Dual IDH1/2 inhibitor
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.